TenNor Therapeutics is a leading company focused on the development of new drugs targeting bacterial infections and metabolism-related diseases. The company emphasizes a patient-centered approach, aiming to create therapeutics that hold significant clinical value. TenNor boasts a unique multi-target conjugate molecule technology platform, which is integral to its drug development pipeline. This platform is supported by a globally protected intellectual property framework, allowing the company to advance multiple products into late-stage clinical trials. These products address various indications, including Helicobacter pylori infections, infections related to implanted medical devices, hepatic encephalopathy due to cirrhosis, and diarrhea-predominant irritable bowel syndrome.

The company is backed by an experienced and international research and development management team, which leads its global drug development efforts. TenNor's commitment to innovation is reflected in its ongoing clinical trials, including the promising results from its lead candidate, TNP-2198, which has reached significant endpoints in Phase III trials. The company is also actively engaged in securing funding to accelerate the development and commercialization of its core drug products, highlighting its strategic focus on addressing critical clinical needs in the field of infectious diseases and metabolic disorders.

China

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of “first-in-class” or “best-in-class” new drug products.

TenNor Therapeutics

Company Details